Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
NCT ID: NCT00675194
Last Updated: 2008-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
120 participants
INTERVENTIONAL
2003-10-31
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Furthermore, comparison of progression-free survival, 1-year survival, Quality of Life and safety
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
NCT00397904
A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer
NCT00512681
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
NCT00165464
Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer
NCT01956149
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
NCT04934618
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cisplatin, Irinotecan, Capecitabine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* unidimensional measurable disease
* Karnofsky index \>/=60%
Exclusion Criteria
* colorectal diseases
* brain metastases
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johannes Gutenberg University Mainz
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Markus Moehler, MD
Role: PRINCIPAL_INVESTIGATOR
Johannes Gutenberg University Mainz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johannes Gutenberg Universität , I. Medizinische Klinik und Polokilinik
Mainz, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GC-ICE-2003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.